Enzo Emanuele, MD, PhD, is an Italian clinical pathologist and interdisciplinary researcher with a diverse range of contributions in the field of biomarker medicine. He is the founder and CEO of 2E Science, a private scientific research company. With over 150 peer-reviewed publications, he has gained valuable insight into the academic community and understand the expectations, demands and preferences of researchers, pharmaceutical companies and educational institutions. His goals in establishing 2E Science were not merely profit-driven, but stemmed from his dedication to improving the quality of life, driving social progress, improving overall well-being and advancing our knowledge of the world and ourselves.
Professor Claudio Franceschi graduated from the University of Bologna (Italy) with honors in 1967 with a degree in medicine. He worked as a professor of immunology at the Universities of Padua (1980-86), Modena (1986-1998) and Bologna from 1998 to October 2013. Currently he is Professor Emeritus at the University of Bologna and a member of the Institute of Neurological Sciences of Bologna. Professor Franceschi is the founder of the interdepartmental Luigi Galvani research center at the University of Bologna (Director from 2001 to 2006). He held the position of Dean of the Faculty of Experimental Pathology of the University of Bologna (2010-2012). He was the scientific director of the Italian National Research Center on Aging (1996-2005). Professor Franceschi is the author of more than 720 articles in peer-reviewed journals, the citation index for Scopus is 40,982, the Hirsh index is 95. From 2018, he is the head of the laboratory of systemic medicine of healthy aging at Lobachevsky, Nizhny Novgorod, the Leading Scientist - Principal Investigator of the megagrant "Digital Personalized Healthy Aging Megagrant (CPM-Aging): Network Analysis of Large Multi-Content Data to Search for New Diagnostic, Predictive, and Therapeutic Goals". Since 2010, he has published a number of pioneering studies on human aging based on a cohort of centenarians and their offspring or spouses. Primarily, he noted that centenarians or those over a hundred years old are a model for successful aging without comorbid conditions (illnesses or disorders linked to age), which paved the way to understanding the mechanims of these comorbid conditions (cancer, neurodegeneration, cardiovascular, metabolic and auto-immune disorders, etc.), which are so prevalent in today’s so-called “developed” societies. The variety of approaches he has employed, the quantity and quality of his often-pioneering work, and the insatiable curiosity that has pervaded his work throughout his career together have made him a significant contributor to this still mysterious field of knowledge.
Daniela S. Jopp is Associate Professor at the Institute of Psychology of the University of Lausanne and a member of the Swiss National Center of Competence in Research LIVES Overcoming Vulnerability: Life Course Perspectives. She investigates factors associated with successful development and aging, with a specific focus on psychological mechanisms that enable dealing with critical life events and age-related loss. She has initiated an international network of centenarian studies, allowing to investigate cultural differences. Her recent studies include the Fordham Centenarian Study and the Second Heidelberg Centenarian Study. As leading Principal Investigator, she currently heads a collaboration of researchers in Switzerland which will launch the first interdisciplinary and nation-wide centenarian study in 2020.
Exercise prescription as a co-adjuvant therapy to improve the health and clinical/functional status, and the quality of life and well-being of patients with chronic/genetic disorders (mainly, adult and pediatric cancer, cystic fibrosis, anorexia, Alzheimer’s disease, McArdle’s disease [glycogenosis type V]), pulmonary arterial hypertension, and special populations (pregnant women, oldest old people); numerous randomized controlled trials published on the epidemiological and clinical benefits of physical exercise (included in-hospital programs or interventions in nursing homes). Biological responses and adaptations to exercise (study models: healthy and diseased populations, murine models of disease). Genetics (association studies) of muscle and exercise-related phenotypes. Epidemiology, biology and genetics of human exceptional longevity (centenarians). Epidemiology of physical activity and health.
Peter Martin is an internationally renowned researcher in the area of aging and a leading authority on the role of personality in adult development. His landmark work in understanding factors that contribute to healthful patterns of aging and longevity, as well as his service to the International Centenarian Consortium, have made him a world leader in gerontology. Over the span of his career, Dr. Martin has secured over $11 million in external support, including grants from the National Institutes of Health, National Institute of Mental Health, and National Science Foundation. In 2013, he received a Fulbright U.S. Scholar grant to analyze longevity, health, and family support in Japan and the United States. His integrative research model emphasizes psychological and social development across a person’s lifespan, moving beyond purely genetic factors. Dr. Martin has more than 170 publications to date. His studies of centenarians include communities in Georgia and Iowa within the United States, and overseas studies in Germany, Sweden, India, and Japan — while serving his Ames community on the Heartland Senior Services board of directors, the Healthiest Ames Initiative advisory board, and Iowa State’s faculty senate.
Oscar Ribeiro, PhD in Biomedical Sciences, Psychologist, Auxiliary Professor at the Department of Education and Psychology of the University of Aveiro, and Affiliated Professor at the Institute of Biomedical Sciences Abel Salazar at the University of Porto. He is the PI of the Ageing Cluster Research Group at the Centre for Health Technology and Services Research (CINTESIS) located at the Faculty of Medicine of the University of Porto, and currently the coordinator of one of its hubs at the University of Aveiro (CINTESIS.UA). He is currently the PI of the Oporto Centenarian Study (PT100), and Co-PI / researcher of several projects in the field of ageing. His interests are mostly related to psychological resources of adaptation to exceptional longevity, and active and successful ageing. He collaborates with the Office on Ageing Issues 50+ Association (CA50+) in several community intervention projects and has several national and international publications in peer-review journals in the field of gerontology and geriatrics.
Prof Jean-Marie Robine is an Emeritus Research Professor at INSERM, the French National Institute of Health and Medical Research (www.inserm.fr), within the CERMES3 Research group in Paris and the MMDN Lab in Montpellier where he heads the research team Biodemography of longevity and vitality. He is also an Emeritus Professor at the advanced school Ecole pratique des hautes études (www.ephe.sorbonne.fr) in Paris. He studies human longevity, with the aim of understanding the relations between health and longevity. In particular, he measures the impact that the increase in adult life durations may have on the health status of the elderly population. In his most recent work, he takes into accounting the climate changes. Since its creation in 1989, he has been the coordinator of the International Network on Health Expectancy (REVES), which brings together more some 200 researchers worldwide (www.reves-network.org). He is co-responsible for the development of the International Database on Longevity (IDL) in association with the Max Planck Institute for Demographic Research (Rostock) and INED (Paris). He is the project leader of the healthy longevity project granted by AXA Research Fund: the Five-Country Oldest Old Project (5-COOP). He is also advisor to the Director of INED, the French National Institute on Demographic Studies (www.ined.fr) on longevity and ageing issues. He was the project leader of the European Joint Action EHLEIS (2011-2014) which provided analysis of disability-free life expectancies in the European Union (www.eurohex.eu) and part of the BRIDGE-Health project (2015-2017) which aimed to prepare the transition towards a sustainable and integrated EU health information system (www.bridge-health.eu). He was one of the Directors of the French Research Consortium on ageing and longevity (GDR CNRS 3662, 2014-2017) which prepared the way for ILVV, the French Institut de la Longévité, des Vieillesses et du Vieillissement (ilvv.site.ined.fr) Publications: /www.researcherid.com/rid/F-5439-2011"
Paola Sebastiani, PhD, is a Professor of Biostatistics and Adjunct Professor in Bioinformatics at Boston University. She trained in Mathematics and Statistics in Italy and the United Kingdom, and had faculty positions at University of Perugia (Italy), Imperial College, London (United Kingdom) and University of Massachusetts at Amherst before joining Boston University in 2003. She is director of a training grant for interdisciplinary training of biostatisticians and co-founder and co-director of the Master of Science in Applied Biostatistics. Her work focuses on modeling complex traits and integrative analysis of genetic, genomic and environmental factors using Bayesian machine learning methods. She is particularly interested in healthy aging and extreme human longevity, and collaborates with studies of centenarians to discover factors that help people remain healthy as they age.
Ingmar Skoog became M.D. in 1985, Ph.D. in 1993, specialist in psychiatry 1993, and professor in Psychiatry in 2001. He is currently director for the Centre for Ageing and Health AGECAP, including 16 institutions and 6 faculties at the University of Gothenburg, Sweden, and is leading the Neuropsychiatric Epidemiology Unit (Epinep) at the Sahlgrenska Academy. He has been involved in epidemiological research since 1983, and is PI of the Gothenburg H70 Birth Cohort Studies, including the 95+ study. He has published more than 400 scientific papers, and been invited speaker to more than 300 international meetings. His main research interests are vascular factors in relation to dementia and depression, risk factors for dementia and depression, mental health among centenarians, preclinical Alzheimer’s disease and time-trends in ageing.
Professor Jose Viña is Full Professor in the Department of Physiology (University of Valencia, Spain) and has been working in ageing for over thirty years. He has been leading a successful research group dealing with nutritional aspects, in the first instance, with longevity and, more recently, with frailty and Alzheimer’s disease. His major contributions have been: i) Experimental determination that mitochondria are key targets for ageing; ii) Identification of molecular mechanisms to explain why females live longer than males; iii) Identification of new longevity-associated genes, particularly those involved in p53 pathways, telomerase, RAS/GRF1, and antioxidants (G6PD); iv) Generation of a new experimental model for frailty in animals, and; v) Identification of biomarkers of Alzheimer’s disease and frailty.
Professor Karl-Heinz Wagner is the President of the Austrian Nutrition Society, Leader of the Faculty Focus Nutrition and Ageing, Director of the Research Platform Active Ageing and Vice-Dean of the Faculty of Life Sciences, Univ. of Vienna. The main areas of research of the group include Oxidative stress and DNA Damage, which are linked to the chronic diseases cardiovascular disease, cancer, diabetes type 2 but also to physiological processes like ageing. As an experimental working group, we are focusing on lifestyle triggers such as the diet, single food compounds, phytochemicals, physical activity and physiologically active non- food compounds (e.g. bile pigments) and their effects on Oxidative Stress and DNA Stability mainly in human metabolism by initiating human intervention, cross-sectional or case-control studies. At the bench we are exploring the topic with modern techniques (biomarker) for the determination of antioxidative compounds, biochemical and molecular methods to monitor the oxidation of macromolecules and their oxidation products, approaches for the detection of ROS induced DNA and chromosomal damage, DNA repair and methods used to measure antioxidant enzymes, transcriptional factors and gene responses. Very recently we started to link mechanistic data with epidemiological data from large consortia, particularly regarding bile pigment metabolism. The most important field at the moment we try to connect biomarker to is ageing.
Dr. Willcox is a Professor and Director of Research at the Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii, at the Kuakini Medical Center (KMC) Campus. He is also a Principal Investigator of the NIH-funded Kuakini Hawaii LIFESPAN and HEALTHSPAN Studies and co-Principal Investigator of the Okinawa Centenarian Study. He is also active clinically as a Physician co-Leader of the Long Term Care Hospitalist Service at The Queens Medical Center. Dr. Willcox trained in Medicine at the University of Toronto, Internal Medicine at the Mayo Clinic, and Geriatric Medicine at Harvard Medical School. Dr. Willcox has published widely in the genetic, environmental and clinical aspects of healthy aging, is on the Editorial Board of the Journals of Gerontology, the leading gerontological journal. He has been recognized with a Dorothy Dillon Eweson Award for Advances in Aging Research, the Henry Christian Award from the American Federation for Medical Research, and a Director’s Citation from the Centers for Medicare and Medicaid Services. He is a fellow of the Gerontological Society of America and a three-time nominee for Outstanding Physician of the Year at The Queen’s Medical Center. Dr. Willcox is also an author of a NY Times best-selling book on healthy aging, The Okinawa Program, and his work has appeared in cover articles of Time Magazine, National Geographic, and on Oprah, Good Morning America, NOVA Science, BBC, among other media. Dr. Bradley Willcox Expertfile